Compounds > 7-hydroxy-2-n,n-dipropylaminotetralin
Page last updated: 2024-10-21

7-hydroxy-2-n,n-dipropylaminotetralin and MPTP Neurotoxicity Syndrome

7-hydroxy-2-n,n-dipropylaminotetralin has been researched along with MPTP Neurotoxicity Syndrome in 1 studies

7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation

Research Excerpts

ExcerptRelevanceReference
" Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metabolism and increases bioavailability in the brain."1.39Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice. ( Chen, JC; Hsieh, YT; Kuo, YH; Lao, CL, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lao, CL1
Kuo, YH1
Hsieh, YT1
Chen, JC1

Other Studies

1 other study available for 7-hydroxy-2-n,n-dipropylaminotetralin and MPTP Neurotoxicity Syndrome

ArticleYear
Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
    Neurotoxicity research, 2013, Volume: 24, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum;

2013